Considering the relationship among AGEs, the MAPK/NF-κB signaling pathway, and the effects of TFs on the kidney (described above), TFs may block the MAPK/NF-κB signaling cascade by reducing the level of AGEs in vivo to improve diabetic nephropathy. The gene discussed is NFKB1; the disease is diabetic kidney disease.